Helus Pharma周一表示,其实验性迷幻药物在一项晚期临床试验中,与安慰剂相比,在重度抑郁症患者身上显示出抑郁症状具有统计学意义的改善。该公司在美国上市的股票在盘前交易中上涨逾20%。
Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump Nov 16 - Helus Pharma said on Monday its experimental psychedelic drug showed statistically significant improvement in depression symptoms compared with placebo in patients with major depressive disorder in a late-stage trial. US-listed shares of the company rose more than 20% in premarket trading.
这种名为HLP003的药物是裸盖菇素的改良版本,裸盖菇素是所谓“魔法蘑菇”产生迷幻效果的化合物。它被设计为与标准抗抑郁药联合服用。
The drug, known as HLP003, is a modified version of psilocin, the compound responsible for the psychedelic effects of so-called "magic mushrooms." It is designed to be taken alongside standard antidepressants.
Jefferies分析师表示,HLP003的疗效超出投资者预期,其在第六周的缓解率和反应率“意义重大”,可能代表了“相对于其他迷幻剂的差异化属性”。该研究入组了222名患有中度至重度抑郁症的成年人,所有患者均继续服用其常规抗抑郁药。Helus表示,六周后,服用HLP003的患者在标准抑郁量表上的得分改善了19.5分,而安慰剂组为11.9分。公司补充称,获益最早出现在治疗后两天,并持续至12周。
Jefferies analysts said HLP003's efficacy exceeded investor expectations, while its remission and response rates at week six were "meaningful" and could represent "a differentiating attribute over other psychedelics." The study enrolled 222 adults with moderate to severe depression, all of whom stayed on their usual antidepressants. After six weeks, patients on HLP003 improved by 19.5 points on a standard depression scale, versus 11.9 points for placebo, Helus said. The benefit appeared as early as two days after treatment and lasted through 12 weeks, the company added.
公司还表示,六周后,接受HLP003治疗的患者中有56.3%抑郁症状减少至少一半,安慰剂组为28.2%。服用该药物的患者中,50.9%达到缓解,而安慰剂组为18.2%。
It also said that after six weeks, 56.3% of patients treated with HLP003 saw their depression symptoms cut by at least half, compared with 28.2% among those who received placebo. Of patients on the drug, 50.9% reached remission, versus 18.2% on placebo.
根据美国国立卫生研究院的数据,重度抑郁症是一种常见的精神疾病,可严重损害日常功能和生活质量,每年影响约2100万美国成年人。
Major depressive disorder, a common mental illness that can severely impair daily functioning and quality of life, affects about 21 million US adults annually, according to the National Institutes of Health.
Helus表示,HLP003总体耐受性良好,并补充称大多数副作用为轻度至中度,且发生在给药当天。
HLP003 was generally well tolerated, Helus said, adding that most side effects were mild to moderate and occurred on the day of dosing.
公司称记录了三例治疗相关的严重不良事件,但未发现新的安全性信号。Helus计划进行第二项研究,结果预计在2027年底出炉。
The company said it recorded three treatment-related serious adverse events, but identified no new safety signals. Helus plans a second study, with results expected in late 2027.